Oncolytics Biotech Inc. (ONCY)
After hours:
| Previous Close | 1.0800 |
| Open | 1.0700 |
| Bid | 1.0600 x 400 |
| Ask | 1.0900 x 400 |
| Day's Range | 1.0700 - 1.0890 |
| 52 Week Range | 0.8800 - 3.3900 |
| Volume | |
| Avg. Volume | 255,577 |
| Market Cap | 80.699M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.
- CNW Group
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
- CNW Group
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR). The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for m
